Straits Times Index
3,315.11 +7.21 (+0.22%) Nikkei
38,913.48 +296.38 (+0.77%) Hang Seng
18,943.80 -251.80 (-1.31%) FTSE 100
8,370.33 -46.12 (-0.55%) Bitcoin USD
69,286.35 -643.45 (-0.92%) CMC Crypto 200
1,510.36 -16.06 (-1.05%)
Innate Pharma S.A. (0EVI.IL)
| Previous close | 2.5325 |
| Open | 0.0000 |
| Bid | 2.6550 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 956 |
| Market cap | 219.506M |
| Beta (5Y monthly) | 0.60 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.7800 |
| Earnings date | 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireInnate Pharma: Clarification Regarding SAR443579 Designation
MARSEILLE, France, May 21, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that in an abstract published on 14 May 2024 for the European Hematology Association 2024 Congress on SAR443579/IPH6101, submitted by Sanofi, it was mentioned that the molecule received breakthrough designation. This is an error. The molecule has US FDA Fast Track Designation, as communicated before in June 2023.
Business WireInnate Pharma Highlights Abstracts Selected for EHA 2024 Congress
MARSEILLE, France, May 15, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced today that four abstracts with Innate’s drug candidates have been accepted for the European Association of Hematology (EHA) 2024 Congress, taking place June 13-16, 2024 in Madrid, Spain.
Business WireInnate Pharma Reports First Quarter 2024 Business Update and Financial Results
MARSEILLE, France, May 14, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its consolidated financial results for the quarter ending March 31, 2024.
